Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?

International Journal of Antimicrobial Agents

Volumn 46, Issue 1, 2015, Pages 1-7

  Tsoulas, Christos ^a   Nathwani, Dilip ^b  

^a Institute of Continuing Medical Education of Ioannina   (Greece)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

(MRSA); Daptomycin; Linezolid; Meta analysis; Meticillin resistant Staphylococcus aureus; Skin and soft tissue infection; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; CREATINE KINASE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DELAFLOXACIN; DOXYCYCLINE; LINEZOLID; NEW DRUG; ORITAVANCIN; PENICILLIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TEDIZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ADVERSE DRUG REACTION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GRAM POSITIVE INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; PRURITUS; PUBLICATION; REVIEW; SKIN AND SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; META ANALYSIS; MICROBIOLOGY; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84934940599     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.03.011     Document Type: Review

References (49)

1. Falagas ME. The increasing body of research data in clinical medicine has led to the need for evidence synthesis studies. Preface. Infect Dis Clin North Am 2009; 23:xiii.
2. Glass GV. Primary, secondary, and meta-analysis of research. Educ Res 1976; 5:3-8.
3. Liberati A, Altman DG, Tetzlaff J, Mulrow C., Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62:e1-34.
4. Leibovici L, Falagas ME. Systematic reviews and meta-analyses: how are they done and what are their strengths and limitations. Infect Dis Clin North Am 2009; 23:181-94.
5. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org [accessed 17.11.14].
6. Stevens DL, Bisno AL, Chambers H.F., Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis 2014; 59:e10-52.
7. Liu C, Bayer A, Cosgrove S.E., Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18-55.
8. May AK, Stafford RE, Bulger E.M., Heffernan D., Guillamondegui O, Bochicchio G, et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10:467-99.
9. O'Brien DJ, Gould IM. Does vancomycin have a future in the treatment of skin infections? CurrOpin Infect Dis 2014; 27:146-54.
10. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007; 45 (SUPPL. 3):S191-5.
11. Milkovich G. Future pharmacoeconomic criteria forthe treatment of infections. Int J Antimicrob Agents 2009; 34 (Suppl. 1):S12-4.
12. Ostermann H, Blasi F, Medina J., Pascual E, McBride K, Garau J., et al. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study. J Med Econ 2014; 17:719-29.
13. Nathwani D, Eckmann C, Lawson W., Stephens JM, Macahilig C, Solem CT, et al. Pan-European early switch/early discharge opportunities exist for hospitalized patients with methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections. Clin Microbiol Infect 2014; 20:993-1000.
14. Ying LI, Tang H, Hu Y., Peng F. Effects and safety of linezolid vs. vancomycin for the treatment of patients with MRSA: meta analysis of randomized controlled trials. Chin Pharm J 2011; 46:1041-5.
15. Huang YL, Zhang SZ, Huang Q, Ma H., Lin ZQ. Linezolid versus vancomycin fortreatment of Gram-positive cocci infections: meta-analysis of randomised controlled trials. Chin J Antibiot 2012; 37:545-57.
16. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:53-66.
17. Dodds TJ, Hawke CI. Linezolid versus vancomycin for MRSA skin and soft tissue infections (systematic review and meta-analysis). ANZ J Surg 2009; 79:629-35.
18. Logman JF, Stephens J, Heeg B., Haider S, Cappelleri J, Nathwani D., et al. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 2010; 26:1565-78.
19. Bliziotis IA, Plessa E, Peppas G., Falagas ME. Daptomycin versus other antimicrobial agents forthe treatment of skin and soft tissue infections: a meta-analysis. Ann Pharmacother 2010; 44:97-106.
20. Beibei L, Yun C, Mengli C., Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin forthe treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2010; 35:3-12.
21. Bounthavong M, Hsu DI. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis. Curr Med Res Opin 2010; 26:407-21.
22. Cai Y, Wang R, Liang B., Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-72.
23. Yahav D, Lador A, Paul M., Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963-71.
24. Bounthavong M, Zargarzadeh A, Hsu D.I., Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis. Value Health 2011; 14:631-9.
25. Bally M, Dendukuri N, Sinclair A., Ahern SP, Poisson M, Brophy J. A network metaanalysis of antibiotics fortreatment of hospitalised patients with suspected or proven meticillin-resistant Staphylococcus aureus infection. Int J Antimicrob Agents 2012; 40:479-95.
26. Polyzos KA, Mavros MN, Vardakas K.Z., Makris MC, Rafailidis PI, Falagas ME. Efficacy and safety of telavancin in clinical trials: a systematic review and metaanalysis. PLoS One 2012; 7:e41870.
27. Prasad P, Sun J, Danner R.L., Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-709.
28. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline forthe treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11:834-44.
29. Vardakas KZ, Mavros MN, Roussos N, Falagas ME. Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with Gram-positive infections: focus on the study design. Mayo Clin Proc 2012; 87:349-63.
30. An MM, Shen H, Zhang J.D., Xu GT, Jiang YY. Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2013; 41:426-33.
31. Fu J, Ye X, Chen C, Chen S. The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections. PLoS One 2013; 8:e58240.
32. Yue J, Dong BR, Yang M, Chen X., Wu T, Liu GJ. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev 2013; 7:CD008056.
33. Gurusamy KS, Koti R, Toon C.D., Wilson P., Davidson BR. Antibiotic therapy for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in surgical wounds. Cochrane Database Syst Rev 2013; 8:CD009726.
34. Gurusamy KS, Koti R, Toon C.D., Wilson P., Davidson BR. Antibiotic therapy forthe treatment of methicillin-resistant Staphylococcus aureus (MRSA) in non surgical wounds. Cochrane Database Syst Rev 2013; 11:CD010427.
35. Wang SZ, Hu JT, Zhang C, Zhou W., Chen XF, Jiang LY, et al. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open 2014; 4:e004744.
36. He W, Zhang Y, Chen H., Zhao C, Wang H. Efficacy and safety of daptomycin forthe treatment of infectious disease: a meta-analysis based on randomized controlled trials. J Antimicrob Chemother 2014; 69:3181-9.
37. Katz DE, Lindfield KC, Steenbergen J.N., Benziger DP, Blackerby KJ, Knapp AG, et al. A pilot study of high-dose short duration daptomycin forthe treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria. Int J Clin Pract 2008; 62:1455-64.
38. Davis SL, McKinnon PS, Hall L.M., Delgado Jr G, Rose W, Wilson RF, et al. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. Pharmacotherapy 2007; 27:1611-8.
39. Arbeit RD, Maki D, Tally F.P., Campanaro E., Eisenstein BI. Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.
40. Dryden M, Andrasevic AT, Bassetti M, Bouza E., Chastre J, Cornaglia G, et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010; 16 (Suppl. 1):3-30.
41. Montravers P, Bassetti M, Dupont H., Eckmann C, Heizmann WR, Guirao X, et al. Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 2013; 68 (July (Suppl. 2)):ii15-24.
42. Cavalcanti AB, Goncalves AR, Almeida C.S., Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev 2010; (6):CD007022.
43. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009; 53:4069-79.
44. US Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring, MD: FDA; 2013. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm071185.pdf [accessed 19.03.14].
45. Falagas ME, Vouloumanou EK, Sgouros K, Athanasiou S., Peppas G, Siempos II. Patients included in randomised controlled trials do not represent those seen in clinical practice: focus on antimicrobial agents. IntJ Antimicrob Agents 2010; 36:1-13.
46. Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Dis 2014; 58 (Suppl. 1):S4-9.
47. Leibovici L, Falagas ME. Systematic reviews and meta-analyses in infectious diseases: how are they done and what are their strengths and limitations? Infect Dis Clin North Am 2009; 23:181-94.
48. Itani KM, Dryden MS, Bhattacharyya H, Kunkel M.J., Baruch AM, Weigelt JM. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199:804-16.
49. Nathwani D, Eckmann C, Lawson W., Corman S, Stephens J, Solem C., et al. Weight-based (WB) antibiotic dosing in a real-world European study of complicated skin and soft tissue infections (cSSTI) due to methicillin-resistant S. aureus (MRSA). In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Washington, DC: American Society for Microbiology; 2013 [abstract K-194].